Study of tRNA-Derived Fragment tRF-20-S998LO9D in Pan-Cancer

Jinqi Ma1, Fengxia Liu1

  • 1Department of Blood Transfusion, The Third Xiangya Hospital of Central South University, Changsha 410013, China.

Disease Markers
|May 16, 2022
PubMed
Abstract

Insights

This study reveals that tRNA-derived fragment (tRF)-20-S998LO9D is upregulated across many cancers and linked to poor prognosis. This tRF may act as a cancer-promoting marker in pan-cancer research.

Area of Science:

  • Molecular Biology
  • Genomics
  • Cancer Research

Background:

  • tRNA-derived fragments (tRFs) are emerging as critical regulators in various biological processes.
  • Their role in pan-cancer, however, remains largely unexplored.
  • Understanding tRFs' impact is crucial for developing novel cancer biomarkers and therapeutics.

Purpose of the Study:

  • To investigate the expression and prognostic significance of tRNA-derived fragment (tRF)-20-S998LO9D in pan-cancer.
  • To explore the functional role of tRF-20-S998LO9D in cancer cell proliferation.
  • To predict the underlying molecular mechanisms of tRF-20-S998LO9D in cancer development.

Main Methods:

  • Bioinformatic retrieval of tRF-20-S998LO9D expression data from MINTbase across multiple cancer types.
  • Quantitative PCR (qPCR) for expression validation.
  • In vitro experiments assessing the effect of tRF inhibition on breast and lung cancer cell proliferation.
  • Kaplan-Meier plotter analysis (OncotRF) for prognostic significance.
  • Gene Ontology (GO) and KEGG pathway analyses for mechanism prediction.

Main Results:

  • tRF-20-S998LO9D was found to be highly expressed in breast invasive carcinoma, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, lung squamous cell carcinoma, pheochromocytoma and paraganglioma, and uterine corpus endometrial carcinoma.
  • Inhibition of tRF-20-S998LO9D reduced cell proliferation in MCF-7 (breast) and SK-MES-1 (lung squamous cell carcinoma) cell lines.
  • Elevated tRF-20-S998LO9D levels correlated with poor prognosis in various cancers.
  • tRF-20-S998LO9D is potentially involved in multiple cancer-associated pathways.

Conclusions:

  • tRF-20-S998LO9D is significantly upregulated in a wide spectrum of cancers.
  • Its elevated expression is negatively correlated with patient prognosis, suggesting a cancer-promoting role.
  • tRF-20-S998LO9D represents a potential pan-cancer biomarker for poor prognosis.